Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1251) 1251
Publication (124) 124
Newsletter (43) 43
Book Review (19) 19
Book Chapter (14) 14
Newspaper Article (11) 11
Magazine Article (6) 6
Conference Proceeding (3) 3
Dissertation (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pazopanib (1286) 1286
index medicus (691) 691
oncology (610) 610
humans (589) 589
sunitinib (446) 446
cancer (369) 369
female (334) 334
male (322) 322
metastasis (264) 264
middle aged (262) 262
sorafenib (261) 261
aged (243) 243
care and treatment (238) 238
renal cell carcinoma (225) 225
carcinoma, renal cell - drug therapy (213) 213
adult (203) 203
carcinoma, renal cell (200) 200
kidney neoplasms - drug therapy (197) 197
research (189) 189
drug therapy (187) 187
survival (185) 185
pyrimidines - therapeutic use (184) 184
sulfonamides - therapeutic use (181) 181
chemotherapy (178) 178
interferon-alpha (171) 171
treatment outcome (171) 171
bevacizumab (170) 170
sarcoma (169) 169
antineoplastic agents - therapeutic use (161) 161
pharmacology & pharmacy (157) 157
vascular endothelial growth factor (156) 156
double-blind (150) 150
trial (144) 144
angiogenesis (143) 143
tumors (140) 140
analysis (134) 134
everolimus (133) 133
kidney neoplasms - pathology (132) 132
therapy (132) 132
disease-free survival (126) 126
kidney cancer (126) 126
angiogenesis inhibitors - therapeutic use (124) 124
patients (124) 124
medicine & public health (122) 122
pyrimidines - adverse effects (117) 117
sulfonamides - adverse effects (116) 116
urology & nephrology (116) 116
axitinib (114) 114
dosage and administration (113) 113
endothelial growth-factor (112) 112
tyrosine kinase inhibitor (111) 111
efficacy (110) 110
targeted therapy (110) 110
angiogenesis inhibitors (109) 109
aged, 80 and over (107) 107
clinical trials (107) 107
prognosis (106) 106
renal-cell carcinoma (104) 104
health aspects (103) 103
tyrosine (103) 103
pyrimidines - administration & dosage (100) 100
sulfonamides - administration & dosage (99) 99
tyrosine kinase inhibitors (95) 95
carcinoma, renal cell - pathology (93) 93
patient outcomes (92) 92
hematology, oncology and palliative medicine (86) 86
protein kinase inhibitors - therapeutic use (86) 86
phase-ii (85) 85
cancer therapies (83) 83
antineoplastic agents (81) 81
antineoplastic agents - adverse effects (80) 80
retrospective studies (80) 80
soft tissue sarcoma (80) 80
soft-tissue sarcoma (80) 80
animals (79) 79
metastases (79) 79
carcinoma (78) 78
open-label (77) 77
antimitotic agents (76) 76
development and progression (75) 75
angiogenesis inhibitors - adverse effects (73) 73
antineoplastic combined chemotherapy protocols - therapeutic use (72) 72
vegf (72) 72
complications and side effects (71) 71
pyrimidines - pharmacology (71) 71
young adult (71) 71
neoplasms. tumors. oncology. including cancer and carcinogens (70) 70
article (69) 69
immunotherapy (69) 69
neoplasm metastasis (67) 67
safety (67) 67
hypertension (66) 66
sulfonamides - pharmacology (65) 65
inhibitor (64) 64
expression (63) 63
sarcoma - drug therapy (63) 63
case report (61) 61
carcinoma, renal cell - secondary (60) 60
medical research (59) 59
molecular targeted therapy (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1249) 1249
German (29) 29
French (21) 21
Russian (9) 9
Korean (7) 7
Hungarian (2) 2
Polish (2) 2
Spanish (2) 2
Czech (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Incidence of osteonecrosis of the jaw (ONJ) in metastatic renal cell cancer patients (mRCC) treated with zoledronic acid (ZA)
by Gyergyay, Fruzsina and Nagyivanyi, Krisztian and Biro, Krisztina and Kuronya, Zsofia and Nemeth, Hajnalka and Geczi, Lajos
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e20649 - e20649
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Developments in Systemic Therapy for Soft Tissue and Bone Sarcomas
by George, S
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2019, Volume 17, Issue 5, pp. 625 - 628
The past year has led to significant changes in systemic therapies used to treat soft tissue sarcomas, mainly dominated by the removal of the recently approved... 
PAZOPANIB | ONCOLOGY
Journal Article
Details down arrow
3. Preclinical Evaluation of Oral Metronomic Topotecan and Pazopanib for the Treatment of Aggressive Extracranial Pediatric Solid Tumors
by Kumar, Sushil
11/2013
Low Dose Metronomic (LDM) chemotherapy, combined with VEGF pathway inhibitors, is a highly effective strategy to coordinately inhibit angiogenesis and tumor... 
Angiogenesis | Pediatric cancer | 0992 | Metronomic topotecan | Pazopanib
Dissertation
Details down arrow
4. Full Text The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib
by Mori, Yoshinori and Kinoshita, Shiori and Kanamori, Takashi and Kataoka, Hiromi and Joh, Takashi and Iida, Shinsuke and Takemoto, Masashi and Kondo, Masahiro and Kuroda, Junko and Komatsu, Hirokazu
Internal Medicine, ISSN 0918-2918, 2018
The clinical efficacy and outcomes of pazopanib treatment for metastatic extraosseous Ewing sarcoma remain unclear. We herein report a case of heavily... 
extraosseous Ewing sarcoma | pazopanib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European -rganisation for Research and Truatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072
by Benson, C and Ray-Coquard, I and Sleijfer, S and Litière, S and Blay, J.-Y and Le Cesne, A and Papai, Z and Judson, I and Schöffski, P and Chawla, S and Gil, T and Piperno-Neumann, S and Marréaud, S and Dewji, M.R and Van Der Graaf, W.T.A
Gynecologic Oncology, ISSN 0090-8258, 07/2016, Volume 142, Issue 1, pp. 89 - 94
Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They have a high recurrence rate following surgery, modest... 
Soft tissue sarcoma | Uterine sarcoma | Pazopanib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib
by Sun Young Lee and and Na-ri Lee
The Korean Journal of Internal Medicine, ISSN 1226-3303, 2018, Volume 33, Issue 2, p. 442
induced; Pazopanib | Leiomyosarcoma; Hyperthermia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study
by Hyun-jun Kim and and Youjin Kim and Su Jin Lee and Jeeyun Lee and Se Hoon Park
Journal of Gynecologic Oncology (JGO), ISSN 2005-0380, 2018, Volume 29, Issue 1, p. 1
Objective: In the treatment of metastatic soft tissue sarcoma (STS), pazopanib is considered a standard treatment after failure of chemotherapy. We... 
Sarcoma; Uterus; Endometrium; Pazopanib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase Ib/II study of the safety and efficacy of combination therapy with multikinase vascular endothelial growth factor inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma
by Subbiah, Vivek and Meyer, Christian and Zinner, Ralph and Meric-Bernstam, Funda and Zahurak, Marianna and O’Connor, Ashley and Roszik, Jason and Shaw, Kenna and Ludwig, Joseph and Kurzrock, Razelle and Azad, Nilofer
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 8/2017, Volume 23, Issue 15, pp. 4027 - 4034
MEK | Sarcoma | VEGF | Pazopanib | Trametinib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
by Urbonas, V and Schadendorf, D and Zimmer, L and Danson, S and Marshall, E and Corrie, P and Wheater, M and Plummer, E and Mauch, C and Scudder, C and Goff, M and Love, S B and Mohammed, S B and Middleton, M R
Annals of Oncology, ISSN 0923-7534, 02/2019, Volume 30, Issue 2, pp. 317 - 324
Abstract Background Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt)... 
Phase II | Pazopanib | Trametinib | Braf wild-type | Melanoma | trametinib | SURVIVAL | phase II | NRAS | MEK INHIBITION | ONCOLOGY | melanoma | SELUMETINIB | BRAF wild-type | pazopanib | DOCETAXEL | CANCER | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Surufatinib in advanced well-differentiated neuroendocrine tumors: A multicenter, single-arm, open-label, phase Ib/II trial
by Wang, Wei and Xu, Jianming and Li, Jie and Bai, Chunmei and Xu, Nong and Zhou, Zhiwei and Li, Zhiping and Zhou, Caicun and Jia, Ru and Lu, Ming and Cheng, Yuejuan and Mao, Chenyu and Cheng, Ke and Su, Chunxia and Hua, Ye and Qi, Chuan and Li, Jing and Li, Ke and Sun, Qiaoling and Ren, Yongxin and Su, Weiguo
Clinical Cancer Research, ISSN 1078-0432, 06/2019, Volume 25, Issue 12, pp. 3486 - 3494
Purpose: No antiangiogenic treatment is yet approved for extrapancreatic neuroendocrine tumors (NET). Surufatinib (HMPL-012, previously named sulfatinib) is a... 
DIAGNOSIS | EVEROLIMUS | PAZOPANIB | ONCOLOGY | BEVACIZUMAB | SUNITINIB | DEPOT OCTREOTIDE | INHIBITOR
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma
by Stacchiotti, Silvia and Mir, Olivier and Le Cesne, Axel and Vincenzi, Bruno and Fedenko, Alexander and Maki, Robert G and Somaiah, Neeta and Patel, Shreyaskumar and Brahmi, Mehedi and Blay, Jean Y and Boye, Kjetil and Sundby Hall, Kirsten and Gelderblom, Hans and Hindi, Nadia and Martin‐Broto, Javier and Kosela, Hanna and Rutkowski, Piotr and Italiano, Antoine and Duffaud, Florence and Kobayashi, Eisuke and Casali, Paolo G and Provenzano, Salvatore and Kawai, Akira
The Oncologist, ISSN 1083-7159, 01/2018, Volume 23, Issue 1, pp. 62 - 70
Background Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib and... 
Chemotherapy | Sarcoma | Trabectedin | Alveolar soft part sarcoma | Pazopanib | SOLID TUMORS | EFFICACY | TISSUE SARCOMA | PHASE-II | ANTITUMOR-ACTIVITY | METASTATIC LIPOSARCOMA | ONCOLOGY | SUNITINIB | MUSCULOSKELETAL ONCOLOGY GROUP | TUMOR MICROENVIRONMENT | Sarcomas
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Response to Pazopanib in Patients with Relapsed Osteosarcoma
by Elete, Kunal R and Albritton, Karen H and Akers, Lauren J and Basha, Riyaz and Ray, Anish
Journal of Pediatric Hematology/Oncology, ISSN 1077-4114, 2018, p. 1
Axial skeleton primary tumor, metastatic disease at presentation, incomplete surgical resection, and <90% tumor necrosis have all been known to influence... 
relapsed | pediatric osteosarcoma | pazopanib | MAP | oncology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Prevention of tumor progression in Stewart–Treves syndrome with a low dose of pazopanib
by Yamada, Masayuki and Osada, Shin‐Ichi and Toyoshima, Aya and Yamada, Katsuhiro and Hasunuma, Naoko and Manabe, Motomu
The Journal of Dermatology, ISSN 0385-2407, 07/2019, Volume 46, Issue 7, pp. e263 - e265
DERMATOLOGY | Prevention | Pazopanib | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Pazopanib confers a progression-free survival in a patient with ewing’s sarcoma/primitive neuroectodermal tumor of the lung
by Takigami, Ayako and Yamasawa, Hideaki and Kurosaki, Ayako and Sakamoto, Noritaka and Onuki, Tsugitoshi and Mato, Naoko and Tetsuka, Kenji and Endo, Shunsuke and Niki, Toshiro and Bando, Masashi and Hagiwara, Koichi
Internal Medicine, ISSN 0918-2918, 2019, Volume 58, Issue 9, pp. 1335 - 1339
Ewing’s sarcoma | Pazopanib | Primitive neuroectodermal tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. A Case of Severe Hematological Toxicity in Response to Pazopanib
by Sano, Tomomi and Tanzawa, Yoshikazu and Kobayashi, Eisuke and Nakatani, Fumihiko and Kawai, Akira and Makino, Yoshinori and Iwase, Haruo and Chuman, Hirokazu and Hayashi, Yoshikazu
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 06/2016, Volume 43, Issue 6, pp. 785 - 787
Thrombocytopenia | Pazopanib | Neutropenia
Journal Article
Details down arrow
16. Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3
by Penel, Nicolas
Bulletin du Cancer, ISSN 0007-4551, 09/2017, Volume 104, Issue 9, pp. 705 - 706
Renal cell carcinoma | Adjuvant | Pazopanib
Journal Article
Details down arrow
17. Full Text PISCES: A Horoscope for First-Line Targeted Therapy of Metastatic Renal Cell Carcinoma Reply
by Escudier, B and Porta, C and Powles, T and Eisen, T and Sternberg, CN and Mehmud, F and Cella, D
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2014, Volume 32, Issue 33
TRIAL | BLIND | PAZOPANIB | ONCOLOGY | SUNITINIB | PREFERENCE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Metastatic Renal Cell Carcinoma (mRCC) Clinical Evidence and Quality of Supply in Germany
by Krause, A
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 12/2014, Volume 37, Issue 12, pp. 795 - 795
PAZOPANIB | ONCOLOGY | SUNITINIB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell CarcinomaA Trial of the ECOG-ACRIN Cancer Research Group (E2804)
by Flaherty, KT and Manola, JB and Pins, M and McDermott, DF and Atkins, MB and Dutcher, JJ and George, DJ and Margolin, KA and DiPaola, RS
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2015, Volume 33, Issue 21, pp. 2384 - U88
Purpose On the basis of evidence that resistance to vascular endothelial growth factor (VEGF) receptor inhibition is caused by hypoxia-driven residual VEGF and... 
BIOMARKERS | SURVIVAL | INTERFERON-ALPHA | PAZOPANIB | EVEROLIMUS | EFFICACY | ONCOLOGY | DOUBLE-BLIND | SUNITINIB | TOXICITY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
by Suttle, A.B and Ball, H.A and Molimard, M and Hutson, T.E and Carpenter, C and Rajagopalan, D and Lin, Y and Swann, S and Amado, R and Pandite, L
British Journal of Cancer, ISSN 0007-0920, 11/2014, Volume 111, Issue 10, pp. 1909 - 1916
Background: Pazopanib, an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor... 
blood pressure | renal cell carcinoma | pazopanib | progression-free survival | trough concentration | VEGF | PHASE-II | FACTOR RECEPTOR | ANTITUMOR | SU11248 | ORAL PAZOPANIB | ONCOLOGY | IMATINIB | SUNITINIB | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | Blood Pressure | Prognosis | Follow-Up Studies | Humans | Tissue Distribution | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Renal Cell - drug therapy | Biomarkers, Tumor - analysis | Carcinoma, Renal Cell - pathology | Vascular Endothelial Growth Factor Receptor-2 - blood | Survival Rate | Angiogenesis Inhibitors - pharmacokinetics | Kidney Neoplasms - mortality | Sulfonamides - pharmacokinetics | Randomized Controlled Trials as Topic | Carcinoma, Renal Cell - mortality | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - pharmacokinetics | Kidney Neoplasms - pathology | Kidney Neoplasms - drug therapy | Neoplasm Staging | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Index Medicus | Clinical Study
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.